ABUS · CIK 0001447028 · operating
Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on developing therapeutics for chronic hepatitis B virus (HBV) infection. The company's primary product candidate is Imdusiran, a subcutaneously-delivered RNAi therapeutic conjugated with GalNAc that is currently in phase 1 and phase 2a clinical trials. Imdusiran is designed to suppress all HBV antigens, including hepatitis B surface antigen (HBsAg) expression. The company is also developing AB-101, an oral PD-L1 inhibitor in phase 1a/1b trials intended to reawaken patients' HBV-specific immune response by inhibiting the PD-L1 checkpoint.
Arbutus operates under a licensing agreement with Alnylam Pharmaceuticals to develop and commercialize products utilizing LNP delivery technology. The company is incorporated in British Columbia, Canada, and maintains its principal operations in Warminster, Pennsylvania.
With 44 full-time employees and a market capitalization of approximately $0.9 billion, Arbutus operates at a pre-revenue stage typical of clinical-stage biotechnology companies. The company has not yet generated product revenues and operates as an emerging-stage entity focused on advancing its HBV therapeutic candidates through clinical development.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.38 | $-0.38 | +13.6% | |
| 2023 | $-0.44 | $-0.44 | +4.3% | |
| 2022 | $-0.46 | $-0.46 | +44.6% | |
| 2021 | $-0.83 | $-0.83 | — | |
| 2020 | — | — | — | |
| 2019 | — | $-0.46 | -21.1% | |
| 2018 | $-0.38 | $-0.38 | +75.6% | |
| 2017 | $-1.56 | $-1.56 | +78.5% | |
| 2016 | $-7.24 | $-7.24 | -440.3% | |
| 2015 | $-1.34 | $-1.34 | +25.6% | |
| 2014 | $-1.80 | $-1.80 | -95.7% | |
| 2013 | $-0.92 | $-0.92 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-27 | 0001447028-25-000083 | SEC ↗ |
| 2023-12-31 | 2024-03-05 | 0001447028-24-000035 | SEC ↗ |
| 2022-12-31 | 2023-03-02 | 0001447028-23-000018 | SEC ↗ |
| 2021-12-31 | 2022-03-03 | 0001447028-22-000019 | SEC ↗ |
| 2020-12-31 | 2021-03-04 | 0001447028-21-000021 | SEC ↗ |
| 2019-12-31 | 2020-03-05 | 0001447028-20-000038 | SEC ↗ |
| 2018-12-31 | 2019-03-07 | 0001447028-19-000006 | SEC ↗ |
| 2017-12-31 | 2018-03-16 | 0001628280-18-003276 | SEC ↗ |
| 2016-12-31 | 2017-03-22 | 0001628280-17-002760 | SEC ↗ |
| 2015-12-31 | 2016-03-09 | 0001628280-16-012462 | SEC ↗ |
| 2014-12-31 | 2015-03-13 | 0001171843-15-001398 | SEC ↗ |
| 2013-12-31 | 2014-03-28 | 0001171843-14-001457 | SEC ↗ |